Current Drug Safety is a distinguished peer-reviewed journal published by Bentham Science Publishers, focusing on the critical intersection of pharmacology and toxicology. With an ISSN of 1574-8863 and an E-ISSN of 2212-3911, this journal serves as a platform for the latest research and advances in drug safety, highlighting the importance of pharmacological assessments and toxicity evaluations in therapeutic development and public health. Reaching a broad international audience from its base in the United Arab Emirates, Current Drug Safety offers an invaluable resource for researchers, professionals, and students interested in the dynamic fields of drug research and safety management. Despite a current Q3 categorization in multiple pharmacology and toxicology quartiles for 2023, the journal continues to strive for excellence in the scholarly community, reflecting its commitment to disseminating high-quality research. While not operating under an open access model, articles can be accessed through institutional subscriptions and other platforms, ensuring valuable insights into drug safety are available to those who need it most.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

Therapeutics and Clinical Risk Management is a pioneering journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of medication safety, pharmacology, and clinical risk management through rigorous research and comprehensive reviews. With an impact factor that demonstrates its significance within various disciplines, this Open Access journal has been instrumental since its inception in 2006, promoting the dissemination of knowledge to a global audience without barriers. With its reach spanning categories such as Pharmacology, Medicine, and Chemical Health and Safety, it champions innovative practices and risk assessment methodologies. The journal is recognized in the Q2 quartile for multiple related categories and excels in rank within its field, highlighting its influential contributions to safety and therapeutic practices. By prioritizing the sharing of impactful research, Therapeutics and Clinical Risk Management serves as an indispensable resource for researchers, professionals, and students aiming to enhance clinical outcomes and mitigate risks in therapeutic paradigms.

ANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.

Welcome to the JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, a prestigious open access journal published by FRONTIERS MEDIA SA since 2008, dedicated to advancing research in the fields of pharmacy and pharmaceutical sciences. With its strong rooting in Canada, this journal has established itself within the academic community by consistently delivering high-quality studies and insights, as evidenced by its respectable Q2 ranking in both Medicine (miscellaneous) and Pharmaceutical Science categories for 2023, along with a notable 77th percentile ranking in Pharmaceutical Science on Scopus. Spanning over two decades of publication from 1998 to 2024, the journal focuses on critical research areas including pharmacology, toxicology, and drug development. By providing open access to its articles, the journal ensures that vital scientific information is readily available to researchers, professionals, and students alike, fostering collaboration and innovation within these essential disciplines. We invite you to explore the latest findings and contribute to the ongoing dialogue in pharmaceutical research through this essential platform.

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

Expert Opinion on Drug Safety is a prestigious academic journal dedicated to advancing knowledge in the fields of drug safety and pharmacology. Published by Taylor & Francis Ltd, this journal serves as an essential resource for researchers and professionals seeking to explore the complexities of drug interactions, adverse effects, and risk management. With an impressive impact factor and recognized as a Q1 journal in both the Medicine (Miscellaneous) and Pharmacology (Medical) categories, it ranks favorably at #78 out of 272 in Scopus, placing it in the 71st percentile among its peers. Operating under a rigorous peer-review process, the journal publishes original research, expert reviews, and opinion pieces that contribute to a deeper understanding of drug safety practices. While not an open access journal, it remains a vital platform for disseminating pivotal findings and fostering scholarly dialogue, ensuring that critical insights reach a global audience. With continuous publication from 2002 to 2024, Expert Opinion on Drug Safety is a key reference for anyone involved in pharmaceutical research, healthcare practice, or drug regulation.

Drugs-Real World Outcomes, published by SPRINGERNATURE, is an influential open access journal dedicated to the dissemination of research concerning the real-world impact of pharmacological therapies. Since its inception in 2014, this journal has established a significant presence in the field of Pharmacology, evidenced by its classification in the Q2 quartile for 2023 and a Scopus rank of #141 out of 272 in the medical pharmacology category, placing it in the 48th percentile. The journal’s scope encompasses a diverse range of studies aimed at bridging the gap between clinical research and practical outcomes, making it an essential resource for researchers, healthcare professionals, and students alike. Located in Switzerland, Drugs-Real World Outcomes allows researchers unfettered access to vital data, enhancing knowledge translation and improving health care practices. As it continues to evolve, the journal remains committed to fostering high-quality research that informs and advances the field of pharmacological therapies.

The JOURNAL OF SAFETY RESEARCH, published by Pergamon-Elsevier Science Ltd, stands as a premier platform for scholarly discourse within the domain of safety, risk, reliability, and quality. With an esteemed impact factor and a strong ranking of #38 out of 207 in its category as per Scopus, this journal maintains a distinguished Q1 quartile status, reflecting its influence and significance in advancing safety research since its inception in 1969. Researchers, practitioners, and students alike will find a wealth of knowledge here as the journal explores critical aspects of safety in various contexts, highlighting innovative strategies and empirical findings that contribute to improved safety outcomes globally. Though it operates under a traditional access format, the journal’s extensive repository of articles ensures that vital information remains accessible to its readership. The JOURNAL OF SAFETY RESEARCH is not only a cornerstone for those within the safety engineering field, but also a vital resource for professionals seeking to enhance their understanding of risk management and quality assurance methodologies.

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.